These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1216 related items for PubMed ID: 17162205

  • 1. Apoptotic donor leukocytes limit mixed-chimerism induced by CD40-CD154 blockade in allogeneic bone marrow transplantation.
    Li JM, Gorechlad J, Larsen CP, Waller EK.
    Biol Blood Marrow Transplant; 2006 Dec; 12(12):1239-49. PubMed ID: 17162205
    [Abstract] [Full Text] [Related]

  • 2. Blockade of the CD40/CD154 pathway enhances T-cell-depleted allogeneic bone marrow engraftment under nonmyeloablative and irradiation-free conditioning therapy.
    Pan Y, Luo B, Sozen H, Kalscheuer H, Blazar BR, Sutherland DE, Hering BJ, Guo Z.
    Transplantation; 2003 Jul 15; 76(1):216-24. PubMed ID: 12865813
    [Abstract] [Full Text] [Related]

  • 3. Simultaneous blockade of costimulatory signals CD28-CD80 and CD40-CD154 combined with monoclonal antibody against CD25 induced a stable chimerism and tolerance without graft-versus-host disease in rat.
    Zhu ZX, Fan LY, Wang Q.
    Eur Surg Res; 2011 Jul 15; 46(3):109-17. PubMed ID: 21242693
    [Abstract] [Full Text] [Related]

  • 4. Anti-NK cell treatment induces stable mixed chimerism in MHC-mismatched, T cell-depleted, nonmyeloablative bone marrow transplantation.
    Cho SG, Shuto Y, Soda Y, Nakazaki Y, Izawa K, Uchimaru K, Takahashi S, Tani K, Tojo A, Asano S.
    Exp Hematol; 2004 Dec 15; 32(12):1246-54. PubMed ID: 15588949
    [Abstract] [Full Text] [Related]

  • 5. Rapamycin and T cell costimulatory blockade as post-transplant treatment promote fully MHC-mismatched allogeneic bone marrow engraftment under irradiation-free conditioning therapy.
    Wu T, Sozen H, Luo B, Heuss N, Kalscheuer H, Lan P, Sutherland DE, Hering BJ, Guo Z.
    Bone Marrow Transplant; 2002 Jun 15; 29(12):949-56. PubMed ID: 12098061
    [Abstract] [Full Text] [Related]

  • 6. Anti-mouse CD154 antibody treatment facilitates generation of mixed xenogeneic rat hematopoietic chimerism, prevents wasting disease and prolongs xenograft survival in mice.
    Masaki H, Appel MC, Leahy L, Leif J, Paquin L, Shultz LD, Mordes JP, Greiner DL, Rossini AA.
    Xenotransplantation; 2006 May 15; 13(3):224-32. PubMed ID: 16756565
    [Abstract] [Full Text] [Related]

  • 7. Tolerance induction through megadose bone marrow transplantation with two-signal blockade.
    Lee EN, Lee J, Kim EY, Park HJ, Chang CY, Jung DY, Choi SY, Lee SK, Kwon CH, Joh JW, Kim SJ.
    J Surg Res; 2006 Jan 15; 130(1):102-9. PubMed ID: 16183077
    [Abstract] [Full Text] [Related]

  • 8. Induction of stable long-term mixed hematopoietic chimerism following nonmyeloablative conditioning with T cell-depleting antibodies, cyclophosphamide, and thymic irradiation leads to donor-specific in vitro and in vivo tolerance.
    Mapara MY, Pelot M, Zhao G, Swenson K, Pearson D, Sykes M.
    Biol Blood Marrow Transplant; 2001 Jan 15; 7(12):646-55. PubMed ID: 11787527
    [Abstract] [Full Text] [Related]

  • 9. Lymphohematopoietic graft-vs.-host reactions can be induced without graft-vs.-host disease in murine mixed chimeras established with a cyclophosphamide-based nonmyeloablative conditioning regimen.
    Pelot MR, Pearson DA, Swenson K, Zhao G, Sachs J, Yang YG, Sykes M.
    Biol Blood Marrow Transplant; 1999 Jan 15; 5(3):133-43. PubMed ID: 10392959
    [Abstract] [Full Text] [Related]

  • 10. Complete allogeneic hematopoietic chimerism achieved by in utero hematopoietic cell transplantation and cotransplantation of LLME-treated, MHC-sensitized donor lymphocytes.
    Hayashi S, Hsieh M, Peranteau WH, Ashizuka S, Flake AW.
    Exp Hematol; 2004 Mar 15; 32(3):290-9. PubMed ID: 15003315
    [Abstract] [Full Text] [Related]

  • 11. Induction of donor-specific tolerance in sublethally irradiated recipients by gene therapy.
    Forman D, Tian C, Iacomini J.
    Mol Ther; 2005 Aug 15; 12(2):353-9. PubMed ID: 15939670
    [Abstract] [Full Text] [Related]

  • 12. Graft-facilitating doses of ex vivo activated gammadelta T cells do not cause lethal murine graft-vs.-host disease.
    Drobyski WR, Majewski D, Hanson G.
    Biol Blood Marrow Transplant; 1999 Aug 15; 5(4):222-30. PubMed ID: 10465102
    [Abstract] [Full Text] [Related]

  • 13. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.
    Petersen SL.
    Dan Med Bull; 2007 May 15; 54(2):112-39. PubMed ID: 17521527
    [Abstract] [Full Text] [Related]

  • 14. Addition of treosulfan to a nonmyeloablative conditioning regimen results in enhanced chimerism and immunologic tolerance in an experimental allogeneic bone marrow transplant model.
    Ploemacher RE, Johnson KW, Rombouts EJ, Etienne K, Westerhof GR, Baumgart J, White-Scharf ME, Down JD.
    Biol Blood Marrow Transplant; 2004 Apr 15; 10(4):236-45. PubMed ID: 15077222
    [Abstract] [Full Text] [Related]

  • 15. Protective conditioning against GVHD and graft rejection after combined organ and hematopoietic cell transplantation.
    Strober S.
    Blood Cells Mol Dis; 2008 Apr 15; 40(1):48-54. PubMed ID: 17827036
    [Abstract] [Full Text] [Related]

  • 16. Graft engineering using ex vivo methods to limit GVHD: fludarabine treatment generates superior GVL effects in allogeneic BMT.
    Li JM, Giver CR, Waller EK.
    Exp Hematol; 2006 Jul 15; 34(7):895-904. PubMed ID: 16797417
    [Abstract] [Full Text] [Related]

  • 17. Mesenchymal stem cells enhance the induction of mixed chimerism and tolerance to rat hind-limb allografts after bone marrow transplantation.
    Pan H, Zhao K, Wang L, Zheng Y, Zhang G, Mai H, Han Y, Yang L, Guo S.
    J Surg Res; 2010 May 15; 160(2):315-24. PubMed ID: 19524257
    [Abstract] [Full Text] [Related]

  • 18. Role of immunoregulatory donor T cells in suppression of graft-versus-host disease following donor leukocyte infusion therapy.
    Johnson BD, Becker EE, LaBelle JL, Truitt RL.
    J Immunol; 1999 Dec 15; 163(12):6479-87. PubMed ID: 10586039
    [Abstract] [Full Text] [Related]

  • 19. Recovery from established graft-vs-host disease achieved by bone marrow transplantation from a third-party allogeneic donor.
    Taniguchi Y, Yoshihara S, Hoshida Y, Inoue T, Fujioka T, Ikegame K, Kawakami M, Masuda T, Aozasa K, Kawase I, Ogawa H.
    Exp Hematol; 2008 Sep 15; 36(9):1216-25. PubMed ID: 18599183
    [Abstract] [Full Text] [Related]

  • 20. Increased apoptosis of immunoreactive host cells and augmented donor leukocyte chimerism, not sustained inhibition of B7 molecule expression are associated with prolonged cardiac allograft survival in mice preconditioned with immature donor dendritic cells plus anti-CD40L mAb.
    Lu L, Li W, Zhong C, Qian S, Fung JJ, Thomson AW, Starzl TE.
    Transplantation; 1999 Sep 27; 68(6):747-57. PubMed ID: 10515374
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 61.